Locally administered ocular corticosteroids benefits and risks

Drug Safety

Volumn 25, Issue 1, 2002, Pages 33-55

  McGhee, Charles N J ^a   Dean, Simon ^a   Danesh Meyer, Helen ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; EYE DROPS; HYDROCORTISONE; LENS PROTEIN;

CATARACT; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG PROTEIN BINDING; EYE INFLAMMATION; EYE MOVEMENT; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; KERATITIS; KERATOPATHY; LENS; OINTMENT; OXIDATION; PRIORITY JOURNAL; PTOSIS; REVIEW; SIDE EFFECT; TEAR FILM;

EID: 0036192290     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225010-00004     Document Type: Review

References (241)

1. Corticosteroid therapy of eye disease. Fifty years later
2. Les dangers de la cortisonothérapie locale prolongée
3. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis
4. Glaucoma induced by systemic steroid therapy
5. Elevated intraocular pressure following corticosteroid eye drops
6. Corticosteroid-induced cataracts
7. Pharmacokinetics of ophthalmic corticosteroids
8. Adverse effects from topical steroids
9. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis
10. Association of inhaled corticosteroid use with cataract extraction in elderly patients
11. Inhaled corticosteroids, family history, and risk of glaucoma
12. Review: Systemic absorption of topically applied ocular drugs in humans
13. Ocular complication of topical, peri-ocular, and systemic corticosteroids
14. The effect of ketorolac tromethamine in reducing postoperative inflammation: Double-mask parallel comparison with dexamethasone
15. Dexamethasone versus diclofenac sodium eyedrops to treat inflammation after cataract surgery
16. The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology
17. Penetration of topically administered prednisolone acetate into the human aqueous humor
18. Penetration of topically applied dexamethasone alcohol into human aqueous humor
19. Penetration of topically applied prednisolone sodium phosphate into human aqueous humour
20. Penetration of topically applied betamethasone sodium phosphate into human aqueous humour
21. Penetration of synthetic corticosteroids into human aqueous humour
22. The analysis of corticosteroid acetates by gas chromatography/negative ion chemical ionization mass spectrometry
23. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans
24. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection
25. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose
26. Tetrahydrotriamcinolone and triamcinolone. I. Ocular penetration
27. Detection of prednisolone in vitreous following systemic administration
28. Concentration of clobetasone butyrate in aqueous humour
29. Intraocular penetration of local hydrocortisone and cortisone
30. Methyl and fluoro substituted prednisolones in the blood and aqueous humor of the rabbit
31. The penetration of cortisol into normal and pathologic rabbit eyes
32. The ocular uptake of subconjunctivally injected C 14 hydrocortisone. Part 1. Time and major route of penetration in a normal eye
33. An autioradiographic study of the penetration of subconjunctivally injected hydrocortisone into the normal and inflamed rabbit eye
34. Ocular penetration studies. II. Topical administration of prednisolone
35. Ocular penetration studies. I. Topical administration of dexamethasone
36. Corneal wound healing. I. Inhibition of stromal healing by three dexamethasone derivatives
37. Topically applied steroids in corneal disease. I. The role of inflammation in stromal absorption of dexamethasone
38. Comparative toxicity of dexamethasone and its tertiary butyl acetate ester after topical ocular instillation in rabbits
39. Ocular penetration in rabbits of topically applied dexamethasone
40. Topically applied steroids in corneal disease. 3. The role of drug derivative in stromal absorption of dexamethasone
41. Prednisolone phosphate penetration into and through the cornea
42. Topically applied steroids in corneal disease. IV. The role of drug concentration in stromal absorption of prednisolone acetate
43. Topically applied steroids in corneal disease. V. Dexamethasone alcohol
44. Permeability of the isolated rabbit cornea to corticosteroids
45. Anti-inflammatory effectiveness in the cornea of topically administered prednisolone
46. Corneal absorption of fluorometholone in rabbits. A comparative evaluation of corneal drug transport characteristics in anesthetized and unanesthetized rabbits
47. Studies on intraocular penetration and metabolism of fluorometholone in rabbits: A comparison between dexamethasone and prednisolone acetate
48. Kinetics of topically administered prednisolone acetate. Optimal concentration for treatment of inflammatory keratitis
49. Biological equivalence of ophthalmic prednisolone acetate suspensions
50. Periocular injection of corticosteroids: An experimental evaluation of its role in the treatment of corneal inflammation
51. Drug interaction in the eye. Concurrent corticosteroid-antibiotic therapy for inflammatory keratitis
52. A bioavailability comparison in rabbits of two steroids formulated as high-viscosity gels and reference aqueous preparations
53. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits
54. Fluorometholone acetate. A new ophthalmic derivative of fluorometholone
55. Scleral permeability to hydrocortisone and mannitol in the albino rabbit eye
56. A bioavailability comparison in rabbits after a single topical ocular application of prednisolone acetate formulated as a high-viscosity gel and as an aqueous suspension
57. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes
58. High doses of subconjunctival corticosteroid and antibody-forming cells in the eye and draining lymph nodes
59. Experimental corneal wound strength
60. Orbital infusion of steroids in the rabbit
61. Age-related permeability changes in rabbit corneas
62. Radioactive depot-corticosteroid penetration into monkey ocular tissue. I. Retrobulbar and systemic administration
63. Use of orbital floor steroids in the management of patients with uniocular non-necrotising scleritis
64. Corticosteroids in corneal graft rejection. Oral versus single pulse therapy
65. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis
66. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A)
67. Effect of the herpes simplex virus genome on the response of infection to corticosteroids
68. Ocular absorption of dexamethasone phosphate disodium by the rabbit
69. Effect of derivatization of the bioavailability of ophthalmic steroids. Development of an in vitro method of evaluation
70. Corticosteroid drugs
71. Adrenocorticotrophic hormone: Adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocorticoid hormones
72. Plasma steroid levels and clinical effects after topical application of betamethasone
73. Bioavailability investigation of two different oral formulations of methylprednisolone
74. Methylprednisolone concentrations in the vitreous and the serum after pulse therapy
75. The metabolism of fluorometholone by bovine cornea
76. Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension
77. Clinical evaluation of clobetasone butyrate eye drops in the treatment of anterior uveitis and its effects on intraocular pressure
78. β-adrenergic receptor blocking agents
79. Prolongation of anti-inflammatory effect of prednisolone acetate. Influence of formulation in high-viscosity gel
80. Penetration routes of topically applied eye medications
81. Movement of albumin and dextran through the sclera
82. Radioactive depot-corticosteroid penetration into monkey ocular tissue. II. Subconjunctival administration
83. Intraocular dexamethasone penetration via subconjunctival or retrobulbar injections in rabbits
84. Intraocular penetration kinetics of prednisolone after subconjunctival injection in rabbits
85. Esterase activities in adult rabbit eyes
86. Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema
87. Medical treatment of macular edema in patients with uveitis
88. Ocular dialysis. A new technique for in vivo intraocular pharmacokinetic measurements
89. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis
90. Use of hydrophilic contact lenses to increase ocular penetration of topical drugs
91. Ocular penetration of prednisolone and the hydrophilic contact lens
92. Pilocarpine ocuserts. Long-term clinical trials and selected pharmacodynamics
93. Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections
94. Soluble gentamicin ophthalmic inserts as a drug delivery system
95. Clinical uses of collagen shields
96. Collagen shield drug delivery: Therapeutic concentrations of tobramycin in the rabbit cornea and aqueous humor
97. Prevention of experimental corneal allograft rejection in rabbits using cyclosporin-collagen shields
98. Collagen shield enhancement of topical dexamethasone penetration
99. Device drug delivery to the eye. Collagen shields, iontophoresis, and pumps
100. Methylprednisolone delivery by Hyalobend corneal shields and its effects on rabbit ocular inflammation
101. Topical intrastromal steroid during laser in situ keratomileusis to retard interface keratitis
102. Liposomes in topical drug delivery
103. Transscleral iontophoresis of dexamethasone
104. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy
105. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device
106. Phase II results of an intraocular steroid delivery system for cataract surgery
107. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation
108. Cortisone et tension oculaire
109. Statistical attributes of the steroid hypertensive response in the clinically normal eye: The demonstration of three levels of response
110. Identification of high intraocular pressure responders to topical ophthalmic corticosteroids
111. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone in the normal eye
112. Corticosteroids and intraocular pressure
113. Fluorometholone. Anti-inflammatory and intraocular pressure effects
114. The effect of autonomic agents on the pupil and the intraocular pressure of eyes treated with dexamethasone
115. Corticosteroid glaucoma
116. Acute effects of dexamethasone on intraocular pressure in glaucoma
117. Analysis of the systemic corticosteroid sensitivity of patients with primary open-angle glaucoma
118. Steroids, ocular hypertension, and glaucoma
119. Topical corticosteroids and hereditary in glaucoma
120. Effect of corticosteroids on intraocular pressure and fluid dynamics: 2. The effect of dexamethasone in the glaucomatous eye
121. Inheritance of dexamethasone hypertension and glaucoma
122. High myopia and primary open-angle glaucoma
123. Diabetes mellitus and primary open-angle glaucoma. The XXVII Edward Jackson Memorial Lecture
124. Steroid responsiveness in connective tissue diseases
125. Intraocular pressure response to topical dexamethasone as a predictor for the development of primary open-angle glaucoma
126. The prognosis of corticosteroid-responsive individuals
127. Intraocular pressure response to corticosteroids in children
128. Marked intraocular pressure response to instillation of corticosteroids in children
129. Ocular-hypertensive response to topical steroids in children
130. Evaluation of dexamethasone acetate as a topical ophthalmic formulation
131. Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: Indications, efficacy and side effects
132. The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure
133. Increased intraocular pressure following subconjunctival corticosteroid administration
134. Exudative macular degeneration and intravitreal triamcinolone: 18 Month follow up
135. Necrotizing conjunctival ulceration following subconjunctival depot methylprednisolone injection
136. Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids
137. Hydroxymethylprogesterone. An anti-inflammatory steroid without apparent effect on intraocular pressure
138. Comparative anti-inflammatory efficacy of topical corticosteroids with low glaucoma-inducing potential
139. Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate
140. Effect of fluorometholone (FML) on the intraocular pressure of corticosteroid responders
141. Comparative study of the intraocular pressure effects of fluorometholone 0.1% versus dexamethasone 0.1%
142. The ocular hypertensive effect of 0.25% fluorometholone in corticosteroid responders
143. Intraocular pressure response to topically administered fluorometholone
144. Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis
145. Clobetasone butyrate eye drops. Effect on ocular inflammation and intraocular pressure
146. Double-blind clinical trial of topical steroids in anterior uveitis
147. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis
148. Intraocular pressure response to loteprednol etabonate in known steroid responders
149. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis
150. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation
151. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation
152. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration
153. Collagen, factor VIII antigen, and immunoglobulins in the human aqueous drainage channels
154. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids
155. The effect of dexamethasone on integrin and laminin expression in cultured human trabecular meshwork cells
156. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes
157. Dexamethasone effects of protein synthesis on organ-cultured human trabecular meshwork - Autoradiographical, biochemical, and immunohistochemical study
158. Dexamethasone decreases phagocytosis by human trabecular meshwork cells in situ
159. Detection of glucocorticoid receptors in cultured human trabecular cells
160. Studies of aqueous humor dynamics in man. 1. Measurements in young normal subjects
161. Modulation of myocilin/TIGR expression in human trabecular meshwork
162. Identification of a gene that causes primary open angle glaucoma
163. Prevalence of mutations in TIGR/Myocilin in patients with adult and juvenile primary open-angle glaucoma
164. Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells
165. A novel myosin-like protein (myocilin) expressed in the connecting cilium of the photoreceptor: Molecular cloning, tissue expression, and chromosomal mapping
166. The genetics of open-angle glaucoma: The story of GLCIA and myocilin
167. Cloning and characterization of subtracted cDNAs from a human ciliary body library encoding TIGR, a protein involved in juvenile open angle glaucoma with homology to myosin and olfactomedin
168. Cortisone-induced glaucoma: A report on 44 affected eyes
169. A pharmacoeconomic analysis of rimexolone for the treatment of ophthalmic inflammatory conditions
170. Steroid-induced cataract: New perspective from in vitro and lens culture studies
171. Lens epithelia contain a high-affinity, membrane steroid hormone-binding protein
172. The effects of steroids on the human lens epithelium
173. Inhibition of steroid-induced cataract in rat eyes by administration of vitamin-E ophthalmic solution
174. Anticataract action of vitamin E: Its estimation using an in vitro steroid cataract model
175. Posterior subcapsular cataracts induced by topical corticosteroids following keratoplasty for keratoconus
176. Fluorometholone-induced cataract after photorefractive keratectomy
177. Use of corticosteroids in combination with antimicrobial drugs in the treatment of infectious corneal disease
178. Topically administered corticosteroids: Effect on antibiotic-treated bacterial keratitis
179. Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis
180. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis
181. Corticosteroids in the management of herpetic eye disease
182. Virus reactivation in bitches with a medical history of herpesvirus infection
183. Characterization of dexamethasone-induced reactivation of latent bovine herpesvirus I
184. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis
185. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model
186. Acanthamoeba keratitis. A masquerade of presentation in six cases
187. Epidemiology of microbial keratitis in southern California. A multivariate analysis
188. Severe microbial keratitis in temperate and tropical Western Australia
189. Risk factors in microbial keratitis leading to penetrating keratoplasty
190. Endophthalmitis associated with microbial keratitis
191. Intraocular dexamethasone produces a harmful effect on treatment of experimental Staphylococcus aureus endophthalmitis
192. Timing of dexamethasone treatment in experimental Staphylococcus aureus endophthalmitis
193. Intravitreal dexamethasone in exogenous bacterial endophthalmitis: Results of a prospective randomised study
194. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis
195. A comparison of two ophthalmic steroid-antibiotic combinations after cataract surgery
196. Evaluation of infectious crystalline keratitis with confocal microscopy in a case series
197. Infectious crystalline keratopathy following trabeculectomy and low-dose topical steroids
198. The effect of steroidal and nonsteroidal anti-inflammatory agents on corneal re-epithelialization
199. Corticosteroid effects on the corneal surface of rabbits studied by scanning electron microscopy
200. The effect of steroids on the healing of the corneal endothelium. An in vivo and in vitro study in rabbits
201. Effect of topical anti-inflammatory drugs on corneal and limbal wound healing
202. Healing velocity of corneal epithelium evaluated by computer. The effect of topical steroid
203. Effect of corticosteroids on rabbits corneal keratocytes after photorefractive keratectomy
204. In vitro effects of dexamethasone on human corneal keratocytes
205. Filtering bleb encapsulation increased by steroid injection
206. Topical vitamin E and hydrocortisone acetate treatment after photorefractive keratectomy
207. Effect of growth factors with dexamethasone on healing of rabbit corneal stromal incisions
208. Reversal of wound strength retardation by addition of insulin to corticosteroid therapy
209. Topical treatment with nerve growth factor for neurotrophic keratitis
210. Corneal wound healing strength with topical antiinflammatory drugs
211. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier
212. Relative mydriasis after photorefractive keratectomy
213. The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy. A prospective, randomized, observer-masked study
214. The effects of topical steroids on refractive outcome and corneal haze, thickness, and curvature after photorefractive keratectomy with a 6.0-mm ablation diameter
215. Essential pharmacology for photorefractive surgery
216. Effect of 0.1% dexamethasone on epithelial, healing in experimental corneal alkali wounds: Morphological changes during the repair process
217. Effect of topically applied 0.1% dexamethasone on endothelial healing and aqueous composition during the repair process of rabbit corneal alkali wounds
218. Topical steroid use in the treatment of ocular alkali burns
219. Effect of ophthalmic prednisolone acetate on the canine adrenal gland and hepatic function
220. Effect in large dogs of ophthalmic prednisolone acetate on adrenal gland and hepatic function
221. Systemic dexamethasone concentration in horses after continued topical treatment with an ophthalmic preparation of dexamethasone
222. Adrenal axis suppression caused by a small dose of a potent topical corticosteroid
223. Effect on adrenal function of topically applied clobetasol propionate (Dermovate)
224. Systemic absorption of topical steroids
225. Topical corticosteroid therapy and pituitary-adrenal function
226. The influence of dexamethasone 0.1% eye drops on plasma cortisol and ACTH concentrations after cataract surgery
227. Infectious crystalline keratopathy
228. Corneal stromal calcification after topical steroid-phosphate therapy
229. Unusual deposits in the superficial corneal stroma following combined use of topical corticosteroid and beta-blocking medication
230. Iatrogenic dry eye: Late effect of topical steroid formulations
231. Orbital rim fat atrophy after repository periocular corticosteroid injection
232. Limitation of motility after periocular corticosteroid injection
233. Retinal and choroidal vascular occlusion following intralesional corticosteroid injection of a chalazion
234. Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma
235. Complications of excimer laser photorefractive surgery
236. Complications of excimer laser photorefractive keratectomy for myopia
237. 'Steroid-induced' mydriasis and ptosis
238. Subconjunctival betamethasone is of benefit after cataract surgery
239. A comparison of prophylactic, topical and subconjunctival treatment in cataract surgery
240. Occlusion of the central retinal artery after retrobulbar corticostemid injection
241. Vitrectomy for accidental intraocular steroid injection